ArticlePloS one2008
On evaluating MHC-II binding peptide prediction methods.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection.PLoS pathogens · 2020Pooled it
- MHCII-peptide presentation: an assessment of the state-of-the-art prediction methods.Frontiers in immunology · 2024Review
- Review
- In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever.Journal of biomedical research · 2017Article
- Dataset size and composition impact the reliability of performance benchmarks for peptide-MHC binding predictions.BMC bioinformatics · 2014Article
- Predicting host tropism of influenza A virus proteins using random forest.BMC medical genomics · 2014Article
- A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.Antimicrobial agents and chemotherapy · 2013Article
- Scrutinizing MHC-I binding peptides and their limits of variation.PLoS computational biology · 2013Article
- Phylogenetic and phylodynamic analyses of human metapneumovirus in Buenos Aires (Argentina) for a three-year period (2009-2011).PloS one · 2013Article
- PeptX: using genetic algorithms to optimize peptides for MHC binding.BMC bioinformatics · 2011Article
- Peptide binding predictions for HLA DR, DP and DQ molecules.BMC bioinformatics · 2010Article
- T-cell epitope prediction and immune complex simulation using molecular dynamics: state of the art and persisting challenges.Immunome research · 2010Article
- Computer aided selection of candidate vaccine antigens.Immunome research · 2010Article
- An integrated approach to epitope analysis I: Dimensional reduction, visualization and prediction of MHC binding using amino acid principal components and regression approaches.Immunome research · 2010Article
- Prediction of the binding affinities of peptides to class II MHC using a regularized thermodynamic model.BMC bioinformatics · 2010Article
- MHC Class II Binding Prediction-A Little Help from a Friend.Journal of biomedicine & biotechnology · 2010Article
- Critical role of glycosylation in determining the length and structure of T cell epitopes.Immunome research · 2009Article
- NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction.BMC bioinformatics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Choice of one method over another for MHC-II binding peptide prediction is typically based on published reports of their estimated performance on standard benchmark datasets. We show that several standard benchmark datasets of unique peptides used in such studies contain a substantial number of peptides that share a high degree of sequence identity with one or more other peptide sequences in the same dataset. Thus, in a standard cross-validation setup, the test set and the training set are likely to contain sequences that share a high degree of sequence identity with each other, leading to overly optimistic estimates of performance. Hence, to more rigorously assess the relative performance of different prediction methods, we explore the use of similarity-reduced datasets. We introduce three similarity-reduced MHC-II benchmark datasets derived from MHCPEP, MHCBN, and IEDB databases. The results of our comparison of the performance of three MHC-II binding peptide prediction methods estimated using datasets of unique peptides with that obtained using their similarity-reduced counterparts shows that the former can be rather optimistic relative to the performance of the same methods on similarity-reduced counterparts of the same datasets. Furthermore, our results demonstrate that conclusions regarding the superiority of one method over another drawn on the basis of performance estimates obtained using commonly used datasets of unique peptides are often contradicted by the observed performance of the methods on the similarity-reduced versions of the same datasets. These results underscore the importance of using similarity-reduced datasets in rigorously comparing the performance of alternative MHC-II peptide prediction methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.